Skip to content

Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing

Tissue Oxygenation and miR-210 Role In Wound Healing

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02024243
Acronym
miR210
Enrollment
54
Registered
2013-12-31
Start date
2015-10-01
Completion date
2023-03-08
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Ulcer Leg/Foot, Non-Diabetic Patients, Wound Leg

Keywords

Micro RNA, Wound, Chronic Venous Leg Ulcer, VLU, miR210, Indiana University Health Comprehensive Wound Center (CWC)

Brief summary

Hypothesis: Elevated miR210 in the epidermis (outer layer of skin) of ischemic human wound edge tissue (tissue that has a lack of blood flow to it) is associated with poor healing outcome in a setting of standard clinical care. Aim of the study: To determine whether elevated miR-210 in the epidermis of ischemic human wound edge tissue is associated with poor healing outcome in a setting of standard clinical care. This study will last 14 weeks. Adult patients, who are non-diabetic or tightly controlled diabetic, and, who have chronic venous leg ulcers that have been open/not healed for at least 12 weeks, will be enrolled in this study. Patients will be recruited from the Indiana University Health Comprehensive Wound Center (CWC). On days 0, 14 and 28, patients will have the following performed: measurements and photographs taken of their wound; TCOM (transcutaneous oxygen measurement) or ABI to measure the amount of oxygen in the wound tissue, if receiving a tissue biopsy; and two 3-mm punch biopsies from the same wound/ulcer. Biopsies will not be taken if the wound has closed by day 14 or day 28. Additionally, patients' medical records will be reviewed throughout the study for 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed. ABI will be completed per study personnel at initial visit for all consented subjects to ensure subject eligibility (as listed TCOM\<30 mmHg in exclusion criteria). If ABI's are unable to be obtained, TCOM will be performed. There will be a total of 5 visits for this study (6 total visits for patients with open wounds on day 28 of the study). Visits will occur on days 0, 7, 14, 21,28.

Detailed description

The study is designed as 28-day prospective longitudinal observational study including a 98 day (14 week) follow-up photography of the wound to test whether wounds open on day 28 have closed on week 14, or if they have remained chronically open. On days 0, 14 and 28 after enrollment, wound images will be obtained. Wound photographs are a part of standard care when patients come to the Comprehensive Wound Center (CWC). Images do not include the part of body that could lead to identification of the participants. In addition, following standard of care, two biopsies will be taken - one biopsy will be used for laser capture microdissection (LCM) and immunohistochemistry studies, while the other will be used for determination of infection status using quantitative bacterial cultures and Scanning Electron Microscopy (SEM) imaging for biofilm phenotyping. The following will be completed on days 0, 14 and 28: 1. Wound measurements - Photographs for digital planimetry to measure wound area. 2. Two Wound-edge biopsies (3mm) - following wound bed preparation with 1% lidocaine local anesthetic, as required, two punch biopsies (3 mm each) will be obtained from the wound-edge (the leading 3mm edge of the skin at the perimeter) of the same wound/ulcer. 3. Data Collection - the following information will be collected during the enrollment visit and updated at each visit (weekly - on days 0, 7, 14, 21, 28 and 98 (week 14) ), as necessary, and entered onto the data collection form: Age; Sex; Race/Ethnicity; Current medications; Transcutaneous oxygen measurement(TCOM) \<30 mmHg or ABI \< 0.8; Wound location & Etiology; Other associated illnesses; Wound care modality/treatment; and Nutritional status will be recorded as documented by albumin levels and chart records. Healing outcome: Wound photography will be performed every 7 days (every week) as a part of the current standard of care. Based on wound measurements from days 0 and 28 , patients will be classified as either healing or non-healing, per criteria described in the study proposal/protocol. There will be a total of 5 visits for this study (6 total visits for patients with open wounds on day 28 of the study). Visits will occur on days 0, 7, 14, 21 and 28.

Interventions

None listed

Sponsors

Chandan Sen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Ages 30 + years * Presence of 1 or more non-neuropathic venous stasis leg ulcer(s) (VLU) confirmed by vascular duplex * Chronic - Wound open \>4 weeks

Exclusion criteria

* Individuals who are deemed unable to understand the procedures, risks, and benefits of the study (i.e., informed consent) will be excluded * Pregnant women * Diabetes with hemoglobin A1C \> 9% * Subjects with marked immunodeficiency (i.e., patients with HIV/AIDS, organ transplant, and/or cancer) * Inadequate arterial supply, as evidenced by any of the following (for subjects receiving tissue biopsy with wounds below the knee): * TcOM \< 30mmHg * ABI \< 0.7 or \>1.20 * TBI \< 0.6

Design outcomes

Primary

MeasureTime frameDescription
Mean Change of miR210 Expression Across Healing Status (Healing vs. Non-Healing)28 DaysThe primary analysis will compare mean change cycle times (Delta Ct) of the baseline (d1) miR-210 expression across wound healing status (i.e., healing vs non-healing based on d28/d0 wound size (%) using either the two-sample t-test or the non-parametric Wilcoxon rank-sum test depending on the distribution of miR-210 and the homogeneity of the variance across groups.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026